August 24, 2015
2 min read
Save

Vitrectomy to treat endophthalmitis after cataract surgery may not increase visual acuity

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The use of vitrectomy in Medicare beneficiaries was higher than recommended in the Endophthalmitis Vitrectomy Study and may not have an increased benefit in treating endophthalmitis after cataract surgery, according to a study.

Perspective from Cynthia Matossian, MD, FACS

The retrospective cohort study evaluated 615 Medicare beneficiary cases of endophthalmitis that developed within 6 weeks after cataract surgery vs. data from the Endophthalmitis Vitrectomy Study and Endophthalmitis Population Study of Western Australia.

Fifty-eight percent of 502 cases with known culture results were culture positive. Culture-positive cases were more likely than culture-negative cases to have a visual acuity of 20/200 or worse at presentation and at final visit, particularly those with streptococci.

Vitrectomy was performed in 279 cases, which included 85% of patients who had initial acuity of light perception and 41% of patients who had initial acuity better than light perception. Vitrectomy did not improve the chance of achieving 20/40 final visual acuity if patients had an initial acuity of light perception. Among the group that presented with visual acuity better than light perception, 42% of patients with vitrectomy achieved final visual acuity of 20/40 or better vs. 52% of those without vitrectomy.

More than 99% of cases were treated with intravitreal vancomycin, with 97% of patients receiving at least two intravitreal antibiotics.

Overall, 34% of patients had a final visual acuity of 20/200 or worse. Worse initial acuity and older age at diagnosis were predictors of poor final acuity. – by Kristie L. Kahl

Disclosure: The authors report no relevant financial disclosures.